Homocysteine as a Predictor of Early Neurological Deterioration in Acute Ischemic Stroke

Abstract

Background: Ischemic stroke (AIS) is on the rise owing in part to a longer average life expectancy. It's called early neurological deterioration (END) when symptoms deteriorate immediately after the stroke, and it's connected with a decreased probability of recovery. As homocysteine levels rise, so does the risk of neurotoxicity and other conditions that contribute to thrombosis. There are a number of ways that homocysteine may be hazardous, including direct toxicity and endothelium damage, according to experiments. If homocysteine could predict early neurological impairment after an ischemic stroke, this research would have been a success. Patients with acute ischemic stroke were included in the trial at Mataria teaching Hospital (AIS). The participants in the study were, on average, 63 years old and 12 months old. Two-thirds of the participants were men (60.0 percent ). The majority of individuals had hypertension (86.0 percent). One-fifth of research participants had diabetes mellitus (52.0 percent ) More over a third of the participants admitted to smoking cigarettes (44.0 percent ). More than one-third of the participants had dyslipidemia and coronary artery disease (approximately a quarter). The average HbA1c level in this research was 5.8%, with a standard variation of 1.3 percentage points.. It varied from a low of 2 to a high of 176, with an average of 11.5. Some 42.0 percent of the participants had elevated homocysteine concentrations. Age (P-value = 0.657), gender (P-value = 0.368), hypertension (P-value = 0.075), diabetes mellitus (P-value = 0.086), smoking (P-value = 0.171), and dyslipidemia (P-value = 0.726) were found to be non-significant variations across the groups. There was a statistically significant association between early neurological deterioration and a higher median CRP (47.5) compared to those with no decrease (10). Homocysteine levels were greater in individuals with early neurological degeneration (786%) than in those without deterioration (278%) (P = 0.001). Age (P=0.056), gender (P=0.815), high blood pressure (P=0.009), diabetes mellitus (P=0.603), or high cholesterol (P=0.863) were not linked to low homocysteine levels. HbA1C (P=0.507), CRP (P=0.643), or elevated lipid profiles (P=0.603) did not vary across the groups. Because of our investigation, we discovered a substantial connection between elevated levels of homocysteine and END. Homocysteine levels in acute stroke patients might be used as a prognostic indicator for such individuals.